Advances in Managing High Uric Acid Levels in Cancer Patients
Author Information
Author(s): HH Mahmoud, G Leverger, C Patte, E Harvey, F Lascombes
Primary Institution: Service d'Hematologie et d'Oncologie, Hopital d'Enfants Armand Trousseau, Paris, France
Hypothesis
Is the recombinant urate oxidase SR29142 effective in reducing uric acid levels in patients at risk of acute tumour lysis syndrome?
Conclusion
SR29142 is a well-tolerated and fast-acting treatment that effectively reduces uric acid levels in cancer patients.
Supporting Evidence
- SR29142 led to a rapid decline of uric acid levels below measurable levels within 4 hours in all patients receiving a dose of more than 0.10 mg kg-1.
- Preliminary results from 63 patients showed a marked decline in uric acid levels in 62 patients after the first dose of SR29142.
- Patients treated with Uricozyme had a greater decrease in plasma uric acid levels compared to those treated with allopurinol.
Takeaway
This study shows that a new treatment can quickly lower high uric acid levels in cancer patients, helping them start chemotherapy faster.
Methodology
A phase I, single-centre, open-label trial was conducted with 28 healthy male volunteers receiving varying doses of SR29142.
Limitations
The study primarily involved healthy volunteers, and results in patients may vary.
Participant Demographics
28 healthy male volunteers participated in the trial.
Want to read the original?
Access the complete publication on the publisher's website